newsfilter
← Latest News
PR Newswire·

Calliditas Year-end report, January - December 2023

Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successes OCTOBER – DECEMBER 2023 (COMPARED ...